Vaccine development for hepatitis C

M. Lechmann, T. Jake Liang

Research output: Contribution to journalArticle

Abstract

Given the global disease burden and public health impact of hepatitis C, the development of an effective vaccine is of paramount importance. However, many challenging obstacles loom ahead of this goal. The hepatitis C virus (HCV), being an RNA virus, can mutate rapidly in adaptation to the environment, thus contributing to the high sequence divergence of multiple viral isolates in the world. The highest heterogeneity has been found in the hypervariable region of the envelope glycoprotein 2, which contains a principal neutralization epitope. HCV also causes persistent infection in a high percentage of immunocompetent hosts despite active immune response. The lack of an efficient tissue culture system for propagating HCV and testing neutralizing antibodies adds further complexity to the task of vaccine development. The immunologic correlates associated with disease progression or protection are yet to be defined, but recent studies suggest that a vigorous multispecific cellular immune response is important in the resolution of infection. Induction of high-titer, long-lasting, and cross-reactive antienvelope antibodies and a vigorous multispecific cellular immune response that includes both helper and cytotoxic T lymphocytes may be necessary for an effective vaccine. Several promising approaches have been used to develop an HCV vaccine. Novel vaccine candidates based on molecular technology such as recombinant proteins, peptides, viruslike particles, naked DNA, and recombinant viruses are being explored. The final vaccine product may require multiple components that target various aspects of protective immunity. Finally, sterilizing immunity may not be necessary ira vaccine can be developed to prevent chronic infection, which is the major cause of morbidity and mortality from this disease.

Original languageEnglish (US)
Pages (from-to)211-226
Number of pages16
JournalSeminars in Liver Disease
Volume20
Issue number2
StatePublished - 2000
Externally publishedYes

Fingerprint

Hepatitis C
Vaccines
Hepacivirus
Cellular Immunity
Immunity
Infection
Active Immunity
DNA Viruses
RNA Viruses
Cytotoxic T-Lymphocytes
Helper-Inducer T-Lymphocytes
Neutralizing Antibodies
Recombinant Proteins
Disease Progression
Epitopes
Glycoproteins
Public Health
Technology
Morbidity
Peptides

Keywords

  • Antibody
  • Cytotoxic T cell
  • Immune response
  • Protective immunity
  • Recombinant subunit vaccine
  • T helper cell

ASJC Scopus subject areas

  • Hepatology

Cite this

Lechmann, M., & Jake Liang, T. (2000). Vaccine development for hepatitis C. Seminars in Liver Disease, 20(2), 211-226.

Vaccine development for hepatitis C. / Lechmann, M.; Jake Liang, T.

In: Seminars in Liver Disease, Vol. 20, No. 2, 2000, p. 211-226.

Research output: Contribution to journalArticle

Lechmann, M & Jake Liang, T 2000, 'Vaccine development for hepatitis C', Seminars in Liver Disease, vol. 20, no. 2, pp. 211-226.
Lechmann M, Jake Liang T. Vaccine development for hepatitis C. Seminars in Liver Disease. 2000;20(2):211-226.
Lechmann, M. ; Jake Liang, T. / Vaccine development for hepatitis C. In: Seminars in Liver Disease. 2000 ; Vol. 20, No. 2. pp. 211-226.
@article{6b13bb9df5234a96bac8501a35817977,
title = "Vaccine development for hepatitis C",
abstract = "Given the global disease burden and public health impact of hepatitis C, the development of an effective vaccine is of paramount importance. However, many challenging obstacles loom ahead of this goal. The hepatitis C virus (HCV), being an RNA virus, can mutate rapidly in adaptation to the environment, thus contributing to the high sequence divergence of multiple viral isolates in the world. The highest heterogeneity has been found in the hypervariable region of the envelope glycoprotein 2, which contains a principal neutralization epitope. HCV also causes persistent infection in a high percentage of immunocompetent hosts despite active immune response. The lack of an efficient tissue culture system for propagating HCV and testing neutralizing antibodies adds further complexity to the task of vaccine development. The immunologic correlates associated with disease progression or protection are yet to be defined, but recent studies suggest that a vigorous multispecific cellular immune response is important in the resolution of infection. Induction of high-titer, long-lasting, and cross-reactive antienvelope antibodies and a vigorous multispecific cellular immune response that includes both helper and cytotoxic T lymphocytes may be necessary for an effective vaccine. Several promising approaches have been used to develop an HCV vaccine. Novel vaccine candidates based on molecular technology such as recombinant proteins, peptides, viruslike particles, naked DNA, and recombinant viruses are being explored. The final vaccine product may require multiple components that target various aspects of protective immunity. Finally, sterilizing immunity may not be necessary ira vaccine can be developed to prevent chronic infection, which is the major cause of morbidity and mortality from this disease.",
keywords = "Antibody, Cytotoxic T cell, Immune response, Protective immunity, Recombinant subunit vaccine, T helper cell",
author = "M. Lechmann and {Jake Liang}, T.",
year = "2000",
language = "English (US)",
volume = "20",
pages = "211--226",
journal = "Seminars in Liver Disease",
issn = "0272-8087",
publisher = "Thieme Medical Publishers",
number = "2",

}

TY - JOUR

T1 - Vaccine development for hepatitis C

AU - Lechmann, M.

AU - Jake Liang, T.

PY - 2000

Y1 - 2000

N2 - Given the global disease burden and public health impact of hepatitis C, the development of an effective vaccine is of paramount importance. However, many challenging obstacles loom ahead of this goal. The hepatitis C virus (HCV), being an RNA virus, can mutate rapidly in adaptation to the environment, thus contributing to the high sequence divergence of multiple viral isolates in the world. The highest heterogeneity has been found in the hypervariable region of the envelope glycoprotein 2, which contains a principal neutralization epitope. HCV also causes persistent infection in a high percentage of immunocompetent hosts despite active immune response. The lack of an efficient tissue culture system for propagating HCV and testing neutralizing antibodies adds further complexity to the task of vaccine development. The immunologic correlates associated with disease progression or protection are yet to be defined, but recent studies suggest that a vigorous multispecific cellular immune response is important in the resolution of infection. Induction of high-titer, long-lasting, and cross-reactive antienvelope antibodies and a vigorous multispecific cellular immune response that includes both helper and cytotoxic T lymphocytes may be necessary for an effective vaccine. Several promising approaches have been used to develop an HCV vaccine. Novel vaccine candidates based on molecular technology such as recombinant proteins, peptides, viruslike particles, naked DNA, and recombinant viruses are being explored. The final vaccine product may require multiple components that target various aspects of protective immunity. Finally, sterilizing immunity may not be necessary ira vaccine can be developed to prevent chronic infection, which is the major cause of morbidity and mortality from this disease.

AB - Given the global disease burden and public health impact of hepatitis C, the development of an effective vaccine is of paramount importance. However, many challenging obstacles loom ahead of this goal. The hepatitis C virus (HCV), being an RNA virus, can mutate rapidly in adaptation to the environment, thus contributing to the high sequence divergence of multiple viral isolates in the world. The highest heterogeneity has been found in the hypervariable region of the envelope glycoprotein 2, which contains a principal neutralization epitope. HCV also causes persistent infection in a high percentage of immunocompetent hosts despite active immune response. The lack of an efficient tissue culture system for propagating HCV and testing neutralizing antibodies adds further complexity to the task of vaccine development. The immunologic correlates associated with disease progression or protection are yet to be defined, but recent studies suggest that a vigorous multispecific cellular immune response is important in the resolution of infection. Induction of high-titer, long-lasting, and cross-reactive antienvelope antibodies and a vigorous multispecific cellular immune response that includes both helper and cytotoxic T lymphocytes may be necessary for an effective vaccine. Several promising approaches have been used to develop an HCV vaccine. Novel vaccine candidates based on molecular technology such as recombinant proteins, peptides, viruslike particles, naked DNA, and recombinant viruses are being explored. The final vaccine product may require multiple components that target various aspects of protective immunity. Finally, sterilizing immunity may not be necessary ira vaccine can be developed to prevent chronic infection, which is the major cause of morbidity and mortality from this disease.

KW - Antibody

KW - Cytotoxic T cell

KW - Immune response

KW - Protective immunity

KW - Recombinant subunit vaccine

KW - T helper cell

UR - http://www.scopus.com/inward/record.url?scp=0033868504&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033868504&partnerID=8YFLogxK

M3 - Article

C2 - 10946425

AN - SCOPUS:0033868504

VL - 20

SP - 211

EP - 226

JO - Seminars in Liver Disease

JF - Seminars in Liver Disease

SN - 0272-8087

IS - 2

ER -